Personalis, Inc. — Blitz Index 39 (D)
Personalis scores 39 — clinical test volume nearly tripled and clinical revenue rose 11×, held back by a 25.7% gross margin, one pharma customer at 67% of revenue, and a Tempus merger vote on 2026-11-30.
Last re-scored: November 4, 2026.
Confidence: Medium · Category: frontier
Score breakdown
| Section | Score | Detail |
|---|---|---|
| A · Speed | 14 / 25 | Q3 revenue +76.6% on a clinical ramp — test volume nearly tripled and clinical revenue rose 11× ($0.4M → $4.4M), a third axis beside pharma and population sequencing |
| B · Moat | 23 / 60 | A data flywheel (more tests → more genome data → better accuracy) — but a 25.7% gross margin and total costs at 2.4× revenue (B4 3): the moat is a thesis, not economics |
| C · Creative destruction | 10 / 15 | Liquid biopsy and MRD monitoring displacing imaging-led follow-up and tissue biopsy — a real displacement, paced by reimbursement decisions |
| D · BlitzFailing | −8 | Pharma testing at 67% of Q3 revenue with Merck concentration, and clinical tests sold below cost per Medicare (D2 −4); fast cash burn (D1 −2); pricing risk (D4 −2) |
Think we scored it wrong? Score it yourself →
Radar axes (0–100): Moat 38.3 · Speed 56.0 · Creative 66.7.
Watch item
Gates: G1 ✓ (confirmed — clinical ramp: test volume nearly tripled, clinical revenue 11×, Q3 +76.6%) · G2 ✓ (estimated — MRD at ~$4.0–5.5B by 2036, 5–7× the bar, plus liquid-biopsy expansion). 26 points below the 65-point threshold — first score. No FLAG: deductions of 8. Watch: the Tempus merger vote on 2026-11-30 — if it closes, this standalone scoring ends here; if it fails, the ~1.9-year runway becomes the question.
Strengths
- Clinical ramp: test volume nearly tripled, clinical revenue 11×, Q3 revenue +76.6%
- Third axis: pharma ($17.1M) plus population sequencing ($4.1M) plus clinical diagnostics ($4.4M) — a three-part revenue structure
- A large market: MRD at ~$4.0–5.5B by 2036 (5–7× the bar) plus liquid-biopsy expansion
- Data flywheel: rising test volume → accumulating genome data → better accuracy and clinical evidence
- Cash on hand: $190.6M — no short-term liquidity crisis
Concerns
- Low margin: a 25.7% gross margin, operating losses exceeding revenue (total costs of $61.1M versus revenue of $25.6M)
- Fast burn: ~$100M of cash used in 2026, a runway of ~1.9 years if the merger does not close
- Customer concentration: pharma testing at 67% of revenue, high Merck dependence (exact share unconfirmed)
- Medicare below-cost selling: reimbursement and pricing risk sits directly on the growth axis
- Merger uncertainty: the Tempus AI merger closing (vote 2026-11-30) — if it fails, standalone funding is the question
Research notes
Thesis: the clinical ramp is real — and so is the concentration
Personalis enters the BlitzLab record with a first scoring of 39 out of 100, grade D, built from Speed 14 out of 25, Moat 23 out of 60, Creative Destruction 10 out of 15, and deductions of 8. The total sits 26 points below the 65-point line, and the shape of the score is the story: creative destruction converts to 66.7 and speed to 56.0, while the moat converts to only 38.3. This is the genomics company — trailing-twelve-month revenue of about $80.8 million — whose clinical diagnostics ramped in the third quarter: test volume nearly tripled, clinical revenue rose elevenfold from $0.4 million to $4.4 million, and total revenue grew 76.6%. Pharma testing, at $17.1 million, is still 67% of the quarter's revenue, and the gross margin is 25.7% with total costs at 2.4 times revenue. Cash fell from $240.0 million to $190.6 million.
What the company does
Personalis is a genomics company built around NeXT Personal, a blood-based test for minimal residual disease — monitoring whether cancer remains after treatment, from a blood draw rather than a tissue biopsy. It earns money in three lines: pharma testing at $17.1 million in the quarter, up 30% on Merck sample growth; population sequencing at $4.1 million for the VA Million Veteran Program; and clinical diagnostics at $4.4 million, the new axis, up from $0.4 million a year earlier. Total revenue was $25.6 million in the quarter, up 76.6%, and $63.4 million over nine months, up 21%, on trailing revenue of about $80.8 million; clinical test volume reached 13,157, about three times the year-earlier level. The company signed a merger agreement with Tempus AI and has stopped giving guidance and holding earnings calls; a shareholder vote is scheduled for 2026-11-30. At T it is still independent, so it is scored standalone.
Why it scored what it did
Speed is 14 of 25, and the acceleration is real but narrow. Growth (A1, 7) credits the 76.6% quarter and the elevenfold clinical ramp, but nine-month growth of 21% is far below the quarterly rate, so the acceleration rests on one quarter; the quarter grew off a low base of $14.5 million; and growth is mix-dependent, carried by the clinical ramp rather than the pharma base. Capital speed (A2, 2) is the weak link: cash of $190.6 million against guided 2026 cash use of about $100 million and a nine-month net loss of $95.5 million is a runway of about 1.9 years if the merger does not close, with no self-sustaining cash flow. Hiring (A3, 2) is held low because headcount is unconfirmed and total costs of $61.1 million grew 62%, nearly as fast as revenue. Share speed (A4, 3) credits the tripling of test volume as an early share signal, but MRD share against Natera and Guardant is still minimal and no direct share figure is disclosed.
The moat is 23 of 60 — the lowest-converting axis at 38.3. Network effects (B1, 6) are a genuine data flywheel: more tests accumulate more cancer genome data, strengthening accuracy and clinical evidence, with workflow effects from the Merck collaboration — but that is data accumulation, not platform lock-in. Distribution (B2, 7) is a three-channel structure — pharma, VA population sequencing and clinical diagnostics — with Medicare reimbursement as the lever for the clinical channel, except that selling tests below cost eats the economics of that distribution. Market size (B3, 7) passes on the MRD market extrapolated to roughly $4.0–5.5 billion by 2036, five to seven times the bar, plus liquid biopsy at $4–13.6 billion; trailing revenue is about 2% of the MRD market. Gross margin (B4, 3) is the moat's weakest item: 25.7% on gross profit of $6.57 million, with total costs at 2.4 times revenue and an operating loss of $33.8 million. Creative destruction is 10 of 15: tissue biopsy and imaging follow-up give way to blood-based MRD monitoring, but Personalis is one participant in an industry-wide push and the behaviour change is still early.
The risks
Deductions total 8, below the 15-point FLAG line, but they sit on the two axes that carry the growth. Revenue quality (D2, −4) holds three worries: pharma testing is 67% of quarterly revenue and driven by Merck samples, with the exact Merck share unconfirmed; population sequencing of $4.1 million depends on VA government-contract volume; and the 10-Q describes clinical tests being sold below cost, tying reimbursement and pricing risk directly to the growth axis. Debt (D1, −2) is about burn, not borrowings, which are unconfirmed: cash fell from $240.0 million to $190.6 million and the trailing net loss was $119.3 million, so a standalone Personalis needs dilutive funding within about two years. Regulation (D4, −2) is the Medicare side of the same coin — a reimbursement cut would hit clinical revenue of $4.4 million a quarter directly — plus the merger's closing conditions and the 2026-11-30 vote. Governance (D3, 0) records no dual-class or founder-vote disclosure. No large litigation or investigation is confirmed.
What would change the score
The next print decides whether the clinical ramp is a second axis or a single quarter. Sustained clinical growth, pharma concentration falling below 67%, and a gross margin rising from 25.7% — with the below-cost selling resolved — would each strengthen the record. The merger vote on 2026-11-30 is the fork: if it closes, this standalone scoring ends and the burn problem becomes the combined company's; if it does not, the roughly 1.9-year runway returns as the central question.
The gates: both pass — the merger vote may end the story
Gate 1, two pieces of product-market-fit evidence for a growth company, passes on a confirmed basis. The clinical ramp is the evidence — volume nearly tripled, clinical revenue up elevenfold — and it is a third axis beside pharma testing and population sequencing. Gate 2, a ten-year market ceiling at least ten times current revenue, passes as an estimate: the MRD market at roughly $4.0–5.5 billion by 2036 is five to seven times the bar, before liquid-biopsy expansion. The fourth quarter of 2026 has not been reported at T, and its reporting date is unconfirmed — it is not a company-confirmed date and must not be presented as one — and no outcome is anticipated here. That is the balance of the record at T: a genuine ramp on a concentrated base, a margin that has not yet proven itself, and a Tempus merger vote on 2026-11-30 that, if it closes, ends this standalone scoring here.
More Frontier companies
Other Frontier names on the Blitz Index, highest score first: Rocket Lab (62/B), Tesla (62/B), Illumina, Inc. (61/B).
Next earnings
Q4 2026 · Expected
Coverage
Personalis, Inc. · Next earnings unconfirmed at scoring · Score 39 · Grade D
Embed this score
Copy the HTML below to show this score on your site. The badge links back to this page and updates automatically when the score changes.
Preview:
BlitzLab scores businesses against a scholar’s standard — not investment advice. No price targets, no buy/sell recommendations. Figures are from SEC filings (XBRL) as labeled in the source scorecard.